Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 29, 2018 | May 30, 2018 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · Executive Chairman | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270,198 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,644 |
Last balance in matching sequence
After 2026-05-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 626,220 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
| Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
QUEST DIAGNOSTICS INC
Report date May 29, 2018 · Filed May 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2018-05-29 transaction · row 1
1 source rowRow 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000 |
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | IndirectBy Racing Beach Ventures LLC | 7,500 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,797 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 440 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 440 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 24, 2006 · Filed March 28, 2006
Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 209,401 |
Ending reported balance
After 2006-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 635 |
Reported balance
Holding disclosure · report date 2006-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2020 Filed May 7, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 24,349 | $155.57 | $3,787,973.93 |
DisclosureSEC source: 0001209191-20-027672 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,470 | $91.05 | $406,993.50 |
DisclosureSEC source: 0001209191-20-027672 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 35,502 | $96.87 | $3,439,078.74 |
DisclosureSEC source: 0001209191-20-027672 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 24,216 | $187.53 | $4,541,226.48 |
DisclosureSEC source: 0001209191-20-027672 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 40,090 | $234.01 | $9,381,460.90 |
DisclosureSEC source: 0001209191-20-022539 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,491 Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,680 | $238.33 | $400,394.40 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,581 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.56). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 560 | $236.63 | $132,512.80 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,261 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,210 | $235.53 | $284,991.30 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,821 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.07 to $235.72). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,640 | $234.49 | $384,563.60 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,031 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $234.49 (range $233.99 to $234.66). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,017 | $232.96 | $236,920.32 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,671 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $232.96 (range $232.27 to $233.11). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,050 | $231.76 | $243,348.00 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,688 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.76 (range $231.27 to $232.14). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,120 | $230.40 | $258,048.00 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,738 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.40 (range $230.14 to $230.73). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,273 | $229.77 | $522,267.21 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,858 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $229.77 (range $229.07 to $230.00). Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 8,410 | $239.23 | $2,011,924.30 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,131 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,763 | $245.66 | $433,098.58 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,541 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.66 (range $245.32 to $245.92). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,030 | $244.87 | $497,086.10 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,304 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $244.87 (range $244.30 to $245.26). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,971 | $243.65 | $480,234.15 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,334 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.65 (range $243.24 to $244.23). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,241 | $242.61 | $1,028,909.01 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,305 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.61 (range $242.23 to $243.19). Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,680 | $241.78 | $406,190.40 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,546 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $241.78 (range $241.20 to $242.19). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,314 | $241.50 | $2,249,331.00 |
DisclosureSEC source: 0001209191-20-010544 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,226 Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,609 | $248.45 | $1,145,106.05 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,540 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.45 (range $248.02 to $248.97). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,533 | $247.49 | $1,864,342.17 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,149 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.49 (range $246.92 to $247.88). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,433 | $246.27 | $3,554,414.91 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,682 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.27 (range $245.91 to $246.87). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,024 | $245.37 | $3,441,068.88 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,115 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.37 (range $244.91 to $245.90). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,124 | $244.56 | $1,008,565.44 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,139 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.56 (range $243.91 to $244.90). Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,800 | $243.37 | $681,436.00 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,263 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $243.37 (range $242.88 to $243.84). Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 36,755 | $240.95 | $8,856,117.25 |
DisclosureSEC source: 0001209191-20-008878 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,063 Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,818 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F4 · shares: Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO. Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,356 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F3 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 50,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,912 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,502 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · derivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,502 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,032 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,032 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,615 | $212.75 | $2,258,341.25 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $212.75 (range $212.30 to $212.97). Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 23,033 | $211.43 | $4,869,867.19 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,961 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.43 (range $211.08 to $211.97). Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 62,886 | $210.41 | $13,231,843.26 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,994 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.41 (range $210.06 to $210.83). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 32,502 | $131.89 | $4,286,688.78 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 64,032 | $109.14 | $6,988,452.48 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,493 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 13 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,502 Underlying: Common Stock · 1,493 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,941 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 12 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,032 Underlying: Common Stock · 2,941 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,493 | $210.00 | $313,530.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,493 | $131.89 | $196,911.77 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,941 | $210.00 | $617,610.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,941 | $109.14 | $320,980.74 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,683 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 11 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,995 Underlying: Common Stock · 1,683 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,317 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,973 Underlying: Common Stock · 3,317 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,683 | $210.00 | $353,430.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,683 | $131.89 | $221,970.87 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,317 | $210.00 | $696,570.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,317 | $109.14 | $362,017.38 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,532 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · derivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,678 Underlying: Common Stock · 26,532 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.